Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma

Laboratory Investigation

Volumn 85, Issue 4, 2005, Pages 512-521

  Salnikov, Alexei V ^a   Roswall, Pernilla ^b   Sundberg, Christian ^a   Gardner, Humphrey ^c   Heldin, Nils Erik ^b   Rubin, Kristofer ^a,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BIOGEN   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anaplastic thyroid carcinoma; Growth factors; Interleukins; Soluble receptors; Vasculature; Xenograft tumors

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; CYTOKINE; DOXORUBICIN; INTERLEUKIN 1; MESSENGER RNA; PROTEIN NG2; TRANSFORMING GROWTH FACTOR BETA2; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MICROARRAY; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; MACROPHAGE; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; THYROID CARCINOMA; TISSUE PRESSURE;

ANIMALS; DOWN-REGULATION; DOXORUBICIN; EXTRACELLULAR FLUID; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MICE; MICE, NUDE; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 17144428081     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700252     Document Type: Article

References (37)

1. Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-884.
2. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
3. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-819s.
4. Wiig H, Tveit E, Hultborn R, et al. Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand J Clin Lab Invest 1982;42:159-164.
5. 51Cr-EDTA. Int J Cancer 2000;86:636-643.
6. Salnikov AV, Iversen VV, Koisti M, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J 2003;17:1756-1758.
7. Emerich DF, Dean RL, Snodgrass P, et al. Bradykinin modulation of tumor vasculature: II. Activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther 2001;296:632-641.
8. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993;73:1-78.
9. Pietras K, Östman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934.
10. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-5570.
11. Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res 1993;53:4764-4766.
12. Pietras K, Rubin K, Sjöblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances anti-tumor effect of chemotherapy. Cancer Res 2002;62:5476-5484.
13. Pietras K, Stumm M, Hubert M, et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin Cancer Res 2003;9:3779-3787.
14. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
15. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-813.
16. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-8623.
17. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-1559.
18. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607-1615.
19. Lammerts E, Roswall P, Sundberg C, et al. Interference with TGF-β1 and -β3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma. Int J Cancer 2002;102:453-462.
20. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999;84:1212-1222.
21. Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 1994;78:1097-1102.
22. Dahlman T, Lammerts E, Bergström D, et al. Collagen type I expression in experimental anaplastic thyroid carcinoma: regulation and relevance for tumorigenicity. Int J Cancer 2002;98:186-192.
23. Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem 1980;107:303-314.
24. Sundberg C, Ljungström M, Lindmark G, et al. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 1993;143:1377-1388.
25. Reuterdahl C, Sundberg C, Rubin K, et al. Tissue localization of β receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans. J Clin Invest 1993;91:2065-2075.
26. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-3736.
27. Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 2003;4:31-39.
28. Wolman M, Klatzo I, Chui E, et al. Evaluation of the dye-protein tracers in pathophysiology of the bloodbrain barrier. Acta Neuropathol (Berl) 1981;54:55-61.
29. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84:5788-5792.
30. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129.
31. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
32. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
33. Schlingemann RO, Rietveld FJ, de Waal RM, et al. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 1990;136:1393-1405.
34. Stallcup WB. The NG2 proteoglycan: past insights and future prospects. J Neurocytol 2002;31:423-435.
35. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-212.
36. Witmer AN, van Blijswijk BC, van Noorden CJ, et al. In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem 2004;52:39-52.
37. Salven P, Hattori K, Heissig B, et al. Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002;16:1471-1473.